{"ok":true,"entry":{"slug":"olmesartan","kind":"medication","name":"olmesartan","aliases":["Olmetec"],"brands_sg":["Olmetec","Olmezen","Azoren"],"class":"angiotensin receptor blocker","tags":["heart-bp"],"use_for":"high blood pressure, alone or with other bp medicines","use_after":"sg label: once daily · twice-daily offers no advantage","use_duration":null,"take_with":"with or without food, per the sg olmetec label","pros":["sg label: 20 mg once daily is the usual starting dose","label: no initial dose change for older adults","label: no initial change in marked renal impairment"],"cons":["sg label: to be stopped as soon as pregnancy is known","us label: nsaids can blunt it and strain the kidneys","no healthhub leaflet — sg patient-facing info is thin"],"dose_note":"the sg olmetec label sets both the start and the ceiling: \"The usual recommended starting dose of olmesartan medoxomil is 20 mg once daily\", and after two weeks \"the dose of olmesartan medoxomil may be increased to 40 mg. Doses above 40 mg do not appear to have greater effect\" — as directed on the label or by your doctor","dosage":null,"ul_status":null,"sg_class":"prescription-only","cautions":["pregnancy — the sg label says patients who become pregnant should discontinue it as soon as possible","diabetes or kidney impairment while on an aliskiren-containing product — an sg label contraindication","on diuretics or otherwise fluid-depleted — the sg label asks for close medical supervision and consideration of a lower starting dose","potassium supplements, salt substitutes or potassium-sparing diuretics — the us label notes serum potassium may rise"],"clashes":[{"src":["fda_benicar_int"],"note":"us label: co-use may lead to increases in serum potassium; monitoring is advised","with":"potassium supplements, salt substitutes and potassium-sparing diuretics"},{"src":["fda_benicar_int"],"note":"us label: may deteriorate renal function in elderly, volume-depleted or renally impaired patients, and may blunt the blood-pressure effect","with":"nsaids including cox-2 inhibitors"},{"src":["fda_benicar_int2","ndf_olmetec_ci"],"note":"us label: increased risk of renal impairment, hypotension and hyperkalemia; the sg label contraindicates aliskiren in diabetes or renal impairment","with":"ace inhibitors or aliskiren (dual renin-angiotensin blockade)"},{"src":["fda_benicar_int"],"note":"us label: increases in serum lithium concentrations and lithium toxicity have been reported","with":"lithium"},{"src":["fda_benicar_int2"],"note":"us label: olmesartan is to be given at least 4 hours before a colesevelam dose","with":"colesevelam hydrochloride"}],"sources":[{"id":"hsa_register","url":"https://data.gov.sg/api/action/datastore_search?resource_id=d_767279312753558cbf19d48344577084&limit=6000","label":"HSA — Listing of Registered Therapeutic Products (data.gov.sg d_767279312753558cbf19d48344577084), Forensicclassification column; cached at /tmp/hsa_all.json and filtered locally, not re-fetched","quote":"Olmetec Tablet 20mg SIN13016P | Olmesartan medoxomil | Prescription Only | C09CA08; Olmetec Tablet 40mg SIN13018P; OLMEZEN 20MG SIN15530P; OLMEZEN 40MG SIN15528P; Azoren (amlodipine + olmesartan) SIN13964P, SIN13965P, SIN13966P — all 7 olmesartan rows Prescription Only","accessed":"2026-08-27"},{"id":"ndf_olmetec","url":"https://www.ndf.gov.sg/about-drugs/product-information/sin13016p/","label":"MOH National Drug Formulary (Singapore) — Olmetec Tablet 20mg [SIN13016P], product information","quote":"OLMESARTAN MEDOXOMIL - 20 MG … Forensic Classification PRESCRIPTION ONLY MEDICINES … Anatomical Therapeutic Chemical (ATC) code C09CA08 … Prescription-only Medicines with Exemptions for Supply without Prescription NA","accessed":"2026-08-27"},{"id":"ndf_olmetec_ind","url":"https://www.ndf.gov.sg/about-drugs/product-information/sin13016p/","label":"MOH National Drug Formulary (Singapore) — Olmetec [SIN13016P], Indications and Usage","quote":"Olmesartan medoxomil is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents.","accessed":"2026-08-27"},{"id":"ndf_olmetec_dose","url":"https://www.ndf.gov.sg/about-drugs/product-information/sin13016p/","label":"MOH National Drug Formulary (Singapore) — Olmetec [SIN13016P], Dosage and Administration","quote":"The usual recommended starting dose of olmesartan medoxomil is 20 mg once daily … the dose of olmesartan medoxomil may be increased to 40 mg. Doses above 40 mg do not appear to have greater effect.","accessed":"2026-08-27"},{"id":"ndf_olmetec_special","url":"https://www.ndf.gov.sg/about-drugs/product-information/sin13016p/","label":"MOH National Drug Formulary (Singapore) — Olmetec [SIN13016P], special populations and administration","quote":"No initial dosage adjustment is recommended for elderly patients, for patients with moderate to marked renal impairment (creatinine clearance <40 mL/min) or with moderate to marked hepatic dysfunction","accessed":"2026-08-27"},{"id":"ndf_olmetec_admin","url":"https://www.ndf.gov.sg/about-drugs/product-information/sin13016p/","label":"MOH National Drug Formulary (Singapore) — Olmetec [SIN13016P], administration and volume depletion","quote":"Olmesartan medoxomil may be administered with or without food … For patients with possible depletion of intravascular volume … olmesartan medoxomil should be initiated under close medical supervision and consideration should be given to use of a lower starting dose","accessed":"2026-08-27"},{"id":"ndf_olmetec_ci","url":"https://www.ndf.gov.sg/about-drugs/product-information/sin13016p/","label":"MOH National Drug Formulary (Singapore) — Olmetec [SIN13016P], Contraindications","quote":"Patients who become pregnant should discontinue the use of olmesartan medoxomil as soon as possible … The concomitant use of olmesartan medoxomil with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment","accessed":"2026-08-27"},{"id":"fda_benicar_int","url":"https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22BENICAR%22&limit=2","label":"US FDA label — Benicar (olmesartan medoxomil), Cosette Pharmaceuticals, effective 2023-07-12, section 7 Drug Interactions, via openFDA","quote":"Agents increasing potassium levels may lead to increase in serum potassium … NSAID use may lead to increased risk of renal impairment and loss of antihypertensive effect … Lithium: Increases in serum lithium concentrations and lithium toxicity","accessed":"2026-08-27"},{"id":"fda_benicar_int2","url":"https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22BENICAR%22&limit=2","label":"US FDA label — Benicar (olmesartan medoxomil), Cosette Pharmaceuticals, effective 2023-07-12, section 7 Drug Interactions (dual blockade and colesevelam), via openFDA","quote":"Dual inhibition of the renin-angiotensin system: Increased risk of renal impairment, hypotension, and hyperkalemia … Colesevelam hydrochloride: Consider administering olmesartan at least 4 hours before colesevelam hydrochloride dose","accessed":"2026-08-27"},{"id":"hh_404","url":"https://www.healthhub.sg/medication-devices-and-treatment/medications/olmesartan","label":"HealthHub (MOH Singapore) — Medications A–Z: no olmesartan leaflet exists; the URL pattern used for other SG medicines returns a 404 page","quote":"404","accessed":"2026-08-27"}],"brand_certs":null,"updated_at":"2026-08-29T16:16:27.496708+08:00"},"disclaimer":"kozen-x is not a medical device and does not give medical advice. it lists what published sources have written down. absence of a record is not the same as safe."}